NCT07184632

A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

A Study Investigating Safety, Tolerability and Efficacy of Once-weekly NNC0662-0419 in Participants Living With Overweight or Obesity

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 220 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study tests how well different doses of the medicine NNC0662-0419 help people living with overweight or obesity. The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating people living with overweight or obesity. There are 2 study treatments in this study, participants will get either NNC0662-0419, the treatment being tested or placebo, a treatment that has no active medicine in it. NNC0662-0419 is a new medicine which cannot be pre-scribed by doctors but has previously been tested in humans.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	NNC0662-0419	NNC0662-0419 will be administered subcutaneously.
DRUG	Placebo	Placebo matched to NNC0662-0419 will be administered subcutaneously.

Timeline

• Start date: 2025-10-01
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2025-09-22
• Last updated: 2025-12-15

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study